VNDA Stock Risk & Deep Value Analysis
Vanda Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VNDA Stock
We analyzed Vanda Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VNDA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VNDA Risk Analysis & Red Flags
What Could Go Wrong
The company's valuation is almost entirely dependent on the successful regulatory approval and commercialization of tradipitant. A regulatory setback or rejection of tradipitant, coupled with existing unprofitability and a lack of transparent financials, could lead to a significant decline in share price, cash crunch, and substantial shareholder dilution.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Lack of recent transparent financial data (margins, balance sheet, cash flow, latest 10-Q/10-K).
- ⚠
TTM unprofitable with no clear path to self-sustaining profitability without tradipitant success.
- ⚠
15.25% decline in institutional ownership MRQ, signaling eroding confidence.
- ⚠
$200M S-3 shelf registration indicates readiness for potential significant dilution.
Upcoming Risk Events
- 📅
Regulatory rejection or significant delay for tradipitant
- 📅
Higher-than-expected cash burn impacting runway
- 📅
Significant shareholder dilution via S-3 shelf offering
When to Reconsider
- 🚪
Regulatory rejection or significant adverse news for tradipitant in gastroparesis.
- 🚪
Further significant decline in institutional ownership or reported insider selling.
- 🚪
Announced capital raise resulting in substantial shareholder dilution (e.g., >20%).
Unlock VNDA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Vanda Pharmaceuticals Inc (VNDA) Do?
Market Cap
$482.91M
Sector
Healthcare
Industry
Biotechnology
Employees
368
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Visit Vanda Pharmaceuticals Inc WebsiteInvestment Thesis
Vanda Pharmaceuticals presents a highly speculative, high-risk, high-reward opportunity rooted in the potential blockbuster success of tradipitant for gastroparesis, addressing a significant unmet medical need. If regulatory hurdles are overcome and commercialization is robust, the company's valuation could re-rate substantially, potentially yielding a 10x return within 3-5 years. However, the investment is binary and comes with significant financial opacity and negative institutional sentiment.
Is VNDA Stock Undervalued?
Unlock the full AI analysis for VNDA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VNDA Price Targets & Strategy
12-Month Target
$18.18
Bull Case
$40.00
Bear Case
$2.00
Valuation Basis
Based on highly speculative potential for positive tradipitant regulatory updates and re-rating to 18x analyst-projected FY26 EPS of $1.01.
Entry Strategy
Given the lack of technical data, consider a speculative entry only on significant positive news regarding tradipitant or if price drops near previous lows, understanding the high risk.
Exit Strategy
Consider profit-taking if tradipitant receives initial regulatory approval, targeting $18-$25. Set a strict stop-loss if tradipitant faces significant regulatory setbacks or if cash burn accelerates without mitigation.
Portfolio Allocation
1-3% for aggressive risk tolerance due to the binary nature of the investment.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is VNDA Financially Healthy?
Valuation
P/E Ratio
-3.74
Forward P/E
1.01
Profitability
Net Margin
-102.02%
Return on Equity
-23.85%
Revenue Growth
8.70%
EPS
$-3.74
Balance Sheet
Current Ratio
2.39
Quick Ratio
2.38
Debt/Equity
0.01
Cash & Equivalents
$85.32M
Other
Beta (Volatility)
0.58
Does VNDA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable - Potential to expand significantly if tradipitant achieves blockbuster status and secures durable patent protection.
Moat Sources
1 Identified
The durability of Vanda's competitive advantage is weak, relying heavily on the success of a single pipeline candidate (tradipitant) and existing drugs that face competitive pressures and eventual patent expiry. Without strong and diversified IP or market dominance, the moat remains limited.
Moat Erosion Risks
- •Regulatory rejection of tradipitant or similar novel therapies.
- •Introduction of superior or more cost-effective competing treatments for gastroparesis.
- •Patent expirations for Hetlioz and Fanapt leading to generic competition.
VNDA Competitive Moat Analysis
Sign up to see competitive advantages
VNDA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific data available, but typically highly volatile for binary biotech plays.
Institutional Sentiment
Negative - Institutional ownership decreased by 15.25% MRQ.
Insider Activity (Form 4)
No Form 4 filings reported in last 90 days (post-January 12, 2026).
Options Flow
Normal options activity - No specific unusual options activity data provided.
Earnings Intelligence
Next Earnings
2026-05-06 (Q1 2026 announcement)
Surprise Probability
Low - No consensus estimates or historical patterns provided to assess surprise probability.
Historical Earnings Pattern
Unknown - No historical earnings reaction patterns provided.
Key Metrics to Watch
Competitive Position
Top Competitor
ACAD (Acadia Pharmaceuticals)
Market Share Trend
Unknown - No recent market share shifts or threats detailed.
Valuation vs Peers
Cannot accurately compare due to lack of valuation metrics for VNDA and specific peer data. However, analyst EPS forecast of $1.01 for 2026 implies a forward P/E of ~7.15x ($7.22/$1.01), which is significantly lower than typical specialty pharma/biotech, indicating high market skepticism or discounting of future growth.
Competitive Advantages
- •Potential first-mover advantage with tradipitant in gastroparesis if approved.
- •Existing intellectual property and regulatory approvals for Hetlioz and Fanapt.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive VNDA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Announcement (May 6, 2026)
- •Potential update on tradipitant regulatory status for gastroparesis
Medium-Term (6-18 months)
- •If approved, initial commercialization efforts for tradipitant
- •Potential strategic partnerships for pipeline assets
Long-Term (18+ months)
- •Establishment of market leadership in gastroparesis
- •Expansion of pipeline beyond tradipitant
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VNDA?
- ✓
Positive tradipitant regulatory milestones (e.g., PDUFA date announcement, NDA acceptance, Advisory Committee meeting).
- ✓
Demonstrable improvements in cash flow and reduction in cash burn.
- ✓
Announcements of strategic partnerships or licensing agreements for tradipitant.
Bull Case Analysis
See what could go right with Premium
Competing with VNDA
See how Vanda Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc VNDA | $482.9M | 0.8 | -3.7 | $216.1M | -102.0% | 8.7% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Vanda Pharmaceuticals Inc Makes Money
Vanda Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders and rare diseases. It primarily generates revenue from the sales of its two commercialized products: Hetlioz, used to treat Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt, prescribed for schizophrenia. The company's future growth strategy is largely centered on the successful development and regulatory approval of its key pipeline candidate, tradipitant, which is currently being investigated for gastroparesis, a significant unmet medical need. Essentially, Vanda aims to discover, develop, and market specialized drugs for niche patient populations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Vanda Pharmaceuticals Inc (VNDA)?
As of April 12, 2026, Vanda Pharmaceuticals Inc has a DVR Score of 0.8 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vanda Pharmaceuticals Inc?
Vanda Pharmaceuticals Inc's market capitalization is approximately $482.9M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Vanda Pharmaceuticals Inc use?
VNDA is the ticker symbol for Vanda Pharmaceuticals Inc. The company trades on the NGM.
What is the risk level for VNDA stock?
Our analysis rates Vanda Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of VNDA?
Vanda Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of -3.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Vanda Pharmaceuticals Inc's revenue growing?
Vanda Pharmaceuticals Inc has reported revenue growth of 8.7%. The company is growing at a moderate pace.
Is VNDA stock profitable?
Vanda Pharmaceuticals Inc has a profit margin of -102.0%. The company is currently unprofitable.
How often is the VNDA DVR analysis updated?
Our AI-powered analysis of Vanda Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VNDA (Vanda Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.